Related Experiment Video
Updated: May 5, 2026

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass
Abstract:
Micropuncture and morphologic studies were performed in four groups of male Munich-Wistar rats after removal of the right kidney and segmental infarction of two-thirds of the left kidney. Groups 1 and 3 received no specific therapy. Groups 2 and 4 were treated with the angiotensin I converting enzyme inhibitor, enalapril, 50 mg/liter of which was put in their drinking water. All rats were fed standard chow. Groups 1 and 2 underwent micropuncture study 4 wk after renal ablation. Untreated group 1 rats exhibited systemic hypertension and elevation of the single nephron glomerular filtration rate (SNGFR) due to high average values for the mean glomerular transcapillary hydraulic pressure difference and glomerular plasma flow rate. In group 2 rats, treatment with enalapril prevented systemic hypertension and maintained the mean glomerular transcapillary hydraulic pressure gradient at near-normal levels without significantly compromising SNGFR and the glomerular capillary plasma flow rate, as compared with untreated group 1 rats. Groups 3 and 4 were studied 8 wk after renal ablation. Untreated group 3 rats demonstrated persistent systemic hypertension, progressive proteinuria, and glomerular structural lesions, including mesangial expansion and segmental sclerosis. In group 4 rats, treatment with enalapril maintained systemic blood pressure at normal levels over the 8-wk period and significantly limited the development of proteinuria and glomerular lesions. These studies suggest that control of glomerular hypertension effectively limits glomerular injury in rats with renal ablation, and further support the view that glomerular hemodynamic changes mediate progressive renal injury when nephron number is reduced.
Insights
Enalapril, an angiotensin I converting enzyme inhibitor, prevents kidney damage in rats with reduced nephron number. Controlling glomerular hypertension effectively limits kidney injury and progression of renal disease.
Area of Science:
- Nephrology
- Renal Physiology
- Pharmacology
Background:
- Reduced nephron number, as after kidney ablation, can lead to systemic hypertension and glomerular hyperfiltration.
- Glomerular hypertension is a key factor in the progression of kidney disease.
Purpose of the Study:
- To investigate the renoprotective effects of enalapril in a rat model of reduced renal mass.
- To determine if controlling glomerular hypertension mitigates kidney injury.
Main Methods:
- Micropuncture and morphologic studies were conducted on male Munich-Wistar rats following right nephrectomy and left kidney infarction.
- Rats were divided into four groups: untreated and enalapril-treated, studied at 4 and 8 weeks post-ablation.
- Enalapril was administered in drinking water at 50 mg/liter.
Main Results:
- Untreated rats (Group 1) developed hypertension and elevated single nephron glomerular filtration rate (SNGFR).
- Enalapril treatment (Group 2) prevented hypertension and maintained glomerular pressure gradients near normal.
- Long-term enalapril treatment (Group 4) significantly reduced proteinuria and glomerular lesions compared to untreated rats (Group 3).
Conclusions:
- Controlling glomerular hypertension is crucial for limiting kidney injury in the context of reduced nephron mass.
- Glomerular hemodynamic alterations play a significant role in mediating progressive renal injury after nephron reduction.
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Glomerular Filtration Rate and its Regulation
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
Acute Kidney Injury II: Pathophysiology
Diabetic Nephropathy

